Forbes November 14, 2024
Joshua P. Cohen

In June, the Supreme Court overturned the decades-old Chevron doctrine that empowered a federal agency’s “reasonable interpretation of ambiguous federal laws.” This ruling could constrain regulatory agencies, specifically with respect to their latitude in interpreting and operationalizing laws as they see fit.

Since 1984, the Chevron doctrine has served as a framework for federal courts in deciding disputes between federal agencies and private parties over the legality of executive branch decisions and statutory regulations. For example, Congress has granted the Centers for Medicare and Medicaid Services considerable discretion in making policy decisions based on laws that were passed in Congress.

To illustrate, under the Inflation Reduction Act, CMS has been given the authority to select and then negotiate the prices...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Govt Agencies, Insurance, Medicare, Pharma, Pharma / Biotech, Regulations
Medicare’s Selection Of 15 More Drugs For Price Negotiation Puts Spotlight Back On IRA
How Many Physicians Have Opted Out of the Medicare Program? - 2
MedPAC Members Vote to Recommend Pay Hikes for Physicians and Hospitals
Opinion: Former Trump health official: Medicare should cover Wegovy — but not negotiate its price
Medicare will negotiate Novo’s GLP-1 drug price. Here’s what that means for Ozempic, Wegovy.

Share This Article